Engineered T Cells Market by Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes), Application (Breast Cancer, Colorectal Cancer, Leukemia), End-User - Global Forecast 2024-2030

Engineered T Cells Market by Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes), Application (Breast Cancer, Colorectal Cancer, Leukemia), End-User - Global Forecast 2024-2030


The Engineered T Cells Market size was estimated at USD 2.73 billion in 2023 and expected to reach USD 3.43 billion in 2024, at a CAGR 25.72% to reach USD 13.56 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Engineered T Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Engineered T Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Engineered T Cells Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Autolus, Bellicum Pharmaceuticals, Inc., Bristol Myers Squibb, Cabaletta Bio, Inc., ElevateBio, LLC, Elli Lilly and Company, Gilead, Kuur Therapeutics by Athenex, Novartis AG, Oxford BioMedica, Pfizer Inc., Precision Biosciences, Tmunity Therapeutics Inc., and TScan Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Engineered T Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Chimeric Antigen Receptor

T Cell Receptor

Tumor-Infiltrating Lymphocytes
Application
Breast Cancer

Colorectal Cancer

Leukemia

Lung Cancer

Melanoma
End-User
Cancer Research Centers

Clinics

Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Engineered T Cells Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Engineered T Cells Market?
3. What are the technology trends and regulatory frameworks in the Engineered T Cells Market?
4. What is the market share of the leading vendors in the Engineered T Cells Market?
5. Which modes and strategic moves are suitable for entering the Engineered T Cells Market?PDF E-mail From Publisher (2-5)Users License


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Engineered T Cells Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in prevalence of cancer diseases
5.1.1.2. Increasing demand for innovative biopharmaceutical therapies
5.1.1.3. Recent advances in CAR-T cell engineering
5.1.2. Restraints
5.1.2.1. High cost associated to engineered T cells treatment
5.1.3. Opportunities
5.1.3.1. Immuno-oncology sector booming with R&D funding
5.1.3.2. Expanding gene therapy marketspace
5.1.4. Challenges
5.1.4.1. Safety issues and possible side-effects with engineered T cells
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Engineered T Cells Market, by Type
6.1. Introduction
6.2. Chimeric Antigen Receptor
6.3. T Cell Receptor
6.4. Tumor-Infiltrating Lymphocytes
7. Engineered T Cells Market, by Application
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Leukemia
7.5. Lung Cancer
7.6. Melanoma
8. Engineered T Cells Market, by End-User
8.1. Introduction
8.2. Cancer Research Centers
8.3. Clinics
8.4. Hospitals
9. Americas Engineered T Cells Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Engineered T Cells Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Engineered T Cells Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Amgen Inc.
13.1.2. Autolus
13.1.3. Bellicum Pharmaceuticals, Inc.
13.1.4. Bristol Myers Squibb
13.1.5. Cabaletta Bio, Inc.
13.1.6. ElevateBio, LLC
13.1.7. Elli Lilly and Company
13.1.8. Gilead
13.1.9. Kuur Therapeutics by Athenex
13.1.10. Novartis AG
13.1.11. Oxford BioMedica
13.1.12. Pfizer Inc.
13.1.13. Precision Biosciences
13.1.14. Tmunity Therapeutics Inc.
13.1.15. TScan Therapeutics, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. ENGINEERED T CELLS MARKET RESEARCH PROCESS
FIGURE 2. ENGINEERED T CELLS MARKET SIZE, 2023 VS 2030
FIGURE 3. ENGINEERED T CELLS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ENGINEERED T CELLS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ENGINEERED T CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ENGINEERED T CELLS MARKET DYNAMICS
FIGURE 7. ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings